Multi-level insights into the immuno-oncology-microbiome axis: From biotechnology to novel therapies

IF 23.7 Q1 MICROBIOLOGY

iMeta Pub Date : 2024-09-07 DOI:10.1002/imt2.240

Zheshun Pi, Weici Liu, Chenghu Song, Chuandong Zhu, Jiwei Liu, Lu Wang, Zhao He, Chengliang Yang, Lei Wu, Tianshuo Liu, Zijie Geng, Scott J. Tebbutt, Ningning Liu, Yuan Wan, Faming Zhang, Wenjun Mao

{"title":"Multi-level insights into the immuno-oncology-microbiome axis: From biotechnology to novel therapies","authors":"Zheshun Pi, Weici Liu, Chenghu Song, Chuandong Zhu, Jiwei Liu, Lu Wang, Zhao He, Chengliang Yang, Lei Wu, Tianshuo Liu, Zijie Geng, Scott J. Tebbutt, Ningning Liu, Yuan Wan, Faming Zhang, Wenjun Mao","doi":"10.1002/imt2.240","DOIUrl":null,"url":null,"abstract":"<p>The multifaceted interactions among the immune system, cancer cells and microbial components have established a novel concept of the immuno-oncology-microbiome (IOM) axis. Microbiome sequencing technologies have played a pivotal role in not only analyzing how gut microbiota affect local and distant tumors, but also providing unprecedented insights into the intratumor host-microbe interactions. Herein, we discuss the emerging trends of transiting from bulk-level to single cell- and spatial-level analyses. Moving forward with advances in biotechnology, microbial therapies, including microbiota-based therapies and bioengineering-inspired microbes, will add diversity to the current oncotherapy paradigm.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.240","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The multifaceted interactions among the immune system, cancer cells and microbial components have established a novel concept of the immuno-oncology-microbiome (IOM) axis. Microbiome sequencing technologies have played a pivotal role in not only analyzing how gut microbiota affect local and distant tumors, but also providing unprecedented insights into the intratumor host-microbe interactions. Herein, we discuss the emerging trends of transiting from bulk-level to single cell- and spatial-level analyses. Moving forward with advances in biotechnology, microbial therapies, including microbiota-based therapies and bioengineering-inspired microbes, will add diversity to the current oncotherapy paradigm.

查看原文本刊更多论文

免疫肿瘤学-微生物组轴的多层次见解：从生物技术到新型疗法

免疫系统、癌细胞和微生物成分之间多方面的相互作用建立了免疫肿瘤学-微生物组（IOM）轴的新概念。微生物组测序技术不仅在分析肠道微生物群如何影响局部和远处肿瘤方面发挥了关键作用，还为了解肿瘤内宿主与微生物之间的相互作用提供了前所未有的见解。在此，我们将讨论从批量分析过渡到单细胞和空间分析的新趋势。随着生物技术的进步，微生物疗法（包括基于微生物群的疗法和受生物工程启发的微生物）将为当前的肿瘤疗法范式增添多样性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iMeta

CiteScore

10.80

自引率

0.00%

发文量